Cargando…
Evaluation of PDE4 inhibition for COPD
Targeting type 4 phosphodiesterase (PDE4) for treatment of COPD has multilevel benefits to patients by reducing inflammation, relieving bronchoconstriction, and improving pulmonary circulation. The isoenzyme-specific narrow spectrum PDE4 inhibitors such as cilomilast and roflumilast may have limited...
Autores principales: | Wang, Desuo, Cui, Xiangli |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707810/ https://www.ncbi.nlm.nih.gov/pubmed/18044094 |
Ejemplares similares
-
Treating COPD with PDE 4 inhibitors
por: Brown, William M
Publicado: (2007) -
Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014) -
PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
por: Boswell-Smith, Victoria, et al.
Publicado: (2007) -
COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition
por: Singh, Dave, et al.
Publicado: (2020) -
The Role of the Pharmacist in Optimizing Outcomes With Roflumilast, a PDE4 Inhibitor for the Treatment of COPD
por: Williams, Dennis
Publicado: (2020)